<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>With growing epidemiologic and molecular evidence linking the pathogenesis of <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> and <z:e sem="disease" ids="C1326912" disease_type="Neoplastic Process" abbrv="">oncogenesis</z:e>, the role of anti-diabetic drugs as <z:chebi fb="0" ids="35610">antineoplastic agents</z:chebi> becomes a subject of intense investigation </plain></SENT>
<SENT sid="1" pm="."><plain>Several trials are underway assessing the effect of adding <z:chebi fb="0" ids="6801">metformin</z:chebi> to the existing chemotherapy regimen in the treatment of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>This review has a focus on other commonly used drugs classified into two broad groups, incretins and <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>The aim of this review is to discuss the common genetic polymorphisms implicated in the pathogenesis of type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (type 2 DM) and how they are linked to molecular pathways involved in <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
</text></document>